J&J Buyout Of Merck OTC Unit Clears European Commission
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson cleared its final regulatory hurdle toward the acquisition of Merck's stake in the nonprescription drug joint venture following European Commission approval, announced March 30
You may also be interested in...
J&J’s Aciphex Feels The Burn As Rx PPI Market Growth Levels Off
Domestic sales of Johnson & Johnson's Rx proton pump inhibitor Aciphex (rabeprazole 20 mg) were negatively affected by the launch of Procter & Gamble's Prilosec OTC, providing another example of the sluggish growth of the prescription PPI market
J&J’s Aciphex Feels The Burn As Rx PPI Market Growth Levels Off
Domestic sales of Johnson & Johnson's Rx proton pump inhibitor Aciphex (rabeprazole 20 mg) were negatively affected by the launch of Procter & Gamble's Prilosec OTC, providing another example of the sluggish growth of the prescription PPI market
J&J’s Aciphex Feels The Burn As Rx PPI Market Growth Levels Off
Domestic sales of Johnson & Johnson's Rx proton pump inhibitor Aciphex (rabeprazole 20 mg) were negatively affected by the launch of Procter & Gamble's Prilosec OTC, providing another example of the sluggish growth of the prescription PPI market